DE2840498B1 - Pharmaceutical preparations for the treatment of psoriasis - Google Patents

Pharmaceutical preparations for the treatment of psoriasis

Info

Publication number
DE2840498B1
DE2840498B1 DE19782840498 DE2840498A DE2840498B1 DE 2840498 B1 DE2840498 B1 DE 2840498B1 DE 19782840498 DE19782840498 DE 19782840498 DE 2840498 A DE2840498 A DE 2840498A DE 2840498 B1 DE2840498 B1 DE 2840498B1
Authority
DE
Germany
Prior art keywords
parts
acid
fumarate
psoriasis
glycine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
DE19782840498
Other languages
German (de)
Other versions
DE2840498C2 (en
Inventor
Walter Dr Schweckendiek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to DE19782840498 priority Critical patent/DE2840498C2/en
Publication of DE2840498B1 publication Critical patent/DE2840498B1/en
Application granted granted Critical
Publication of DE2840498C2 publication Critical patent/DE2840498C2/en
Expired legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Emergency Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Description

Plv.-Mischung (2) 30 Teile Fumarsäuredimethylester 9 Teile Fumarsäure 10 Teile Calciumsalz des Fumarsäuremonoaethylesters 10 Teile Magnesiumsalz des Fumarsäuremonoaethylesters 10 Teile Zinksalz des Fumarsäuremonoaethylesters 10 Teile Eisensalz des Fumarsäuremonoaethylesters 5 Teile Mangansalz des Fumarsäuremonoaethylesters 1 Teil Kupfersalz des Fumarsäuremonoaethylesters 10 Teile Dilithiumfumarat 5 Teile CaSO4 .2 2 H2O 100 Teile Darauf vermischt man 50 Teile der Mischung (2) mit 30 Teilen Glyzin 8 Teilen Ascorbinsäure 8 Teilen L-Cystein und 4 Teilen L-Methionin Applikation in Gelatinekapseln 0,3 - 0,8 g mit Flüssigkeit, 1 x am Tag direkt vor Frühstück z. B.Plv. Mixture (2) 30 parts of dimethyl fumarate, 9 parts of fumaric acid 10 parts of the calcium salt of fumaric acid monoethyl ester, 10 parts of the magnesium salt of fumaric acid monoethyl ester 10 parts of zinc salt of fumaric acid monoethyl ester 10 parts of iron salt of fumaric acid monoethyl ester 5 parts of manganese salt of fumaric acid monoethyl ester 1 part of copper salt of fumaric acid monoethyl ester 10 parts of dilithium fumarate 5 parts of CaSO4 .2 2 H2O 100 parts and then mix 50 parts of mixture (2) with 30 parts of glycine, 8 parts of ascorbic acid, and 8 parts of L-cysteine and 4 parts of L-methionine application in gelatin capsules 0.3-0.8 g with liquid, 1 x a day directly before breakfast e.g. B.

Claims (1)

Patentanspruch: Internapplizierbare pharmazeutische Zubereitungen zur Behandlung von Psoriasis auf Fumarsäurebasis, mit einem Gehalt einer Mischung von Fumarsäureverbindungen allein oder unter Zusatz von Calciumsulfat, und Glyzin, d a d u r c h g e -k e n n z e i c h n e t, daß auf 80 Gew.-T. dieser Mischung noch a) 8 Gew.-T. Askorbinsäure b) 8 Gew.-T. L-Cystein und c) 4 Gew.-T. L-Methionin enthalten sind. Claim: Pharmaceutical preparations that can be applied internally for the treatment of psoriasis based on fumaric acid, containing a mixture of fumaric acid compounds alone or with the addition of calcium sulfate and glycine, d a d u r c h g e -k e n n n z e i c h n e t that on 80 parts by weight this mixture still a) 8 parts by weight Ascorbic acid b) 8 parts by weight. L-cysteine and c) 4 parts by weight. Contain L-methionine are. Die Erfindung betrifft den im Anspruch genau gekennzeichneten Gegenstand. The invention relates to the subject matter precisely characterized in the claim. Gemäß »Federation Proceedings« 15 (1956) S. According to "Federation Proceedings" 15 (1956) p. 971-976 (D. Shemin) entsteht durch Kondensation von Glyzin mit Succinat O-Aminolaevulinsäure, daraus durch oxydierende Desaminierung os-Ketoglutarsäurehalbaldehyd bzw. -Ketoglutarsäure. Bekanntlich wird diese Säure leicht zu Glutaminsäure transaminiert, die nun ihrerseits z. B. Oxalessigsäure zu Asparaginsäure transam,nieren kann. Es soll damit deutlich gemacht werden, daß man auch ohne den sogenannten Zitronensäurecyclus zur Ketoglutarsäure gelangt. Überdies war Zitronensäure bei der Behandlung von Psoriasis gänzlich wirkungslos. Die Bereitstellung von Glyzin ermöglicht darüber hinaus die Bildung von Serin. In den Schuppen der Psoriatiker fehlen eine Reihe von Aminosäuren oder gewisse Mengen davon, wie z. B. 971-976 (D. Shemin) is produced by the condensation of glycine with succinate O-aminolaevulinic acid, from which os-ketoglutaric acid half-aldehyde by oxidizing deamination or ketoglutaric acid. It is known that this acid is easily transaminated to glutamic acid, which in turn z. B. oxaloacetic acid to aspartic acid can transamate. It is intended to make it clear that one can also without the so-called citric acid cycle reaches ketoglutaric acid. In addition, citric acid has been used in the treatment of psoriasis completely ineffective. The provision of glycine also enables the Formation of serine. A number of amino acids are missing from the psoriatic scales or certain amounts thereof, e.g. B. Glyzin und Asparaginsäure (in der gesunden Haut zu ca.Glycine and aspartic acid (approx. 30% und 6% enthalten). Serin, L-Cystein, L-Methionin und verschiedene andere weisen in den Schuppen ebenfalls ein signifikantes Defizit auf. Es war aber nicht naheliegend, daß gerade diese beiden Aminosäuren zusammen mit Askorbinsäure in genau bezeichneten Mengenverhältnis eine besondes vorteilhafte Wirkung ausüben. Die Behandlung der sogenannten Psoriasisnägel bereitete nämlich noch immer erhebliche Schwierigkeiten. Einbezogen in die Therapie wurde auch Vitamin C. Sie steuert den Abbau der aromatischen Aminosäuresäuren und greift in biologische Oxydationsvorgänge ein, die letzten Endes komplexgesteuerte Reaktionen sind.30% and 6% included). Serine, L-cysteine, L-methionine and various others also show a significant deficit in the scales. But it was It is not obvious that these two amino acids together with ascorbic acid exert a particularly advantageous effect in precisely specified proportions. The treatment of the so-called psoriasis nails was still considerable Trouble. Vitamin C was also included in the therapy. It controls the Degradation of the aromatic amino acid acids and intervenes in biological oxidation processes one, which are ultimately complex-driven reactions. Aus der DE-OS 2530372 ist es zwar bekannt, Fumarsäure, deren Mono- oder Diester zusammen mit Säuren, Alkalisalzen von Askorbinsäure u. anderen Säuren gegen Psoriasis, ggf. noch mit Vitamin-t-Säure zu verabreichen, und aus der DE-OS 27 03 964 ist zwar auch zu entnehmen, daß eine Mischung von Fumarsäuren oder deren Estern und Salzen zusammen mit Glycin und ggf. sekundären Phosphaten zur Behandlung von Psoriasis geeignet ist. Demgegenüber war es aber völlig überraschend, daß die zusätzliche Gabe von L-Methionin und L-Cystein und freier Askorbinsäure in bestimmten Gewichtsverhältnissen eine weitere Verbesserung der Psoviasistherapie bewirkt Der Zusatz dieser drei Verbindungen zu dem bekannten Mitteln beeinflußt nämlich in völlig unerwarteter Weise die bei Psoriasis pathologisch destrukturierten Nägel und auch Kopfhaut in günstiger Weise und führt sie bei entsprechend langer, kontinuierlicher Einnahme von mehreren Monaten in den Normalzustand zurück. Dies konnte bei lange Zeit erfolglos behandelten Psoriatikern in fünf Fällen ohne einzigen Mißerfolg beobachtet werden. From DE-OS 2530372 it is known to use fumaric acid, the mono- or diesters together with acids, alkali salts of ascorbic acid and other acids against psoriasis, possibly to be administered with vitamin t-acid, and from the DE-OS 27 03 964 can also be seen that a mixture of fumaric acids or their Esters and salts together with glycine and possibly secondary phosphates for treatment from psoriasis. In contrast, it was completely surprising that the additional administration of L-methionine and L-cysteine and free ascorbic acid in certain cases Weight ratios further improve psoviasis therapy additive namely, these three connections to the known agent affects in completely unexpectedly the nails pathologically destructured in psoriasis and also Scalp in a favorable manner and leads to it at a correspondingly long, continuous Taking several months back to normal. This could last for a long time Unsuccessfully treated psoriatic patients in five cases without a single failure will. Herstellungsbeispiele für die interne Applikation Plv.-Mischung (1) 24 Teile Fumarsäuredimethylester 8 Teile Fumarsäure 24 Teile Magnesiumfumarat 12 Teile Calciumfumarat 12 Teile Eisenfumarat 1,6 Teile Manganfumarat 0,4 Teile Kupferfumarat 4,0 Teile Dilithiumfumarat 12,0 Teile CaSO4 2 H2O (Gips) 2,0 Teile Zinkoxyd oder Zinkfumarat 100Teile (Mil) Darauf werden 50 Teile der Mischung (1) mit 30 Teilen Glyzin 8 Teilen Ascorbinsäure 8 Teilen L-Cystein 4 Teilen L-Methionin vermischt Applikation in Gelatinekapseln 0,5-1 g. Preparation examples for the internal application of Plv.-Mixture (1) 24 parts of dimethyl fumarate 8 parts of fumaric acid 24 parts of magnesium fumarate 12 Parts calcium fumarate 12 parts iron fumarate 1.6 parts manganese fumarate 0.4 parts copper fumarate 4.0 parts dilithium fumarate 12.0 parts CaSO4 2 H2O (gypsum) 2.0 parts zinc oxide or Zinc fumarate 100 parts (mils) then add 50 parts of mixture (1) with 30 parts Glycine 8 parts ascorbic acid 8 parts L-cysteine 4 parts L-methionine mixed Application in gelatin capsules 0.5-1 g.
DE19782840498 1978-09-18 1978-09-18 Pharmaceutical preparations for the treatment of psoriasis Expired DE2840498C2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE19782840498 DE2840498C2 (en) 1978-09-18 1978-09-18 Pharmaceutical preparations for the treatment of psoriasis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19782840498 DE2840498C2 (en) 1978-09-18 1978-09-18 Pharmaceutical preparations for the treatment of psoriasis

Publications (2)

Publication Number Publication Date
DE2840498B1 true DE2840498B1 (en) 1979-08-02
DE2840498C2 DE2840498C2 (en) 1980-04-10

Family

ID=6049713

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19782840498 Expired DE2840498C2 (en) 1978-09-18 1978-09-18 Pharmaceutical preparations for the treatment of psoriasis

Country Status (1)

Country Link
DE (1) DE2840498C2 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0440298A1 (en) * 1990-01-30 1991-08-07 Brocades Pharma B.V. Topical preparations for treating human nails
WO2000003689A2 (en) * 1998-07-15 2000-01-27 Mandorlo Investment Gmbh Skin and tissue care and/or treatment agent
WO2003005979A2 (en) * 2001-07-07 2003-01-23 Beiersdorf Ag Cosmetic and dermatological preparations containing osmolytes for the treatment and active prevention of dry skin and of other negative alterations in the physiological homeostasis of healthy skin
US7915310B2 (en) * 1998-11-19 2011-03-29 Biogen Idec International Gmbh Utilization of dialkylfumarates
US8399514B2 (en) 2007-02-08 2013-03-19 Biogen Idec Ma Inc. Treatment for multiple sclerosis
US8906420B2 (en) 2009-01-09 2014-12-09 Forward Pharma A/S Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix
US8980832B2 (en) 2003-09-09 2015-03-17 Biogen Idec International Gmbh Use of fumaric acid derivatives for treating cardiac insufficiency, and asthma
US11052062B2 (en) 2004-10-08 2021-07-06 Biogen Swiss Manufacturing Gmbh Controlled release pharmaceutical compositions comprising a fumaric acid ester

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992012952A1 (en) * 1991-01-18 1992-08-06 Dexter Chemical Corporation Malic acid derivatives and compositions for the treatment of psoriasis

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0440298A1 (en) * 1990-01-30 1991-08-07 Brocades Pharma B.V. Topical preparations for treating human nails
EP1639991A3 (en) * 1998-07-15 2007-09-05 Mandorlo Investment GmbH Skin and tissue care and/or treatment composition
WO2000003689A2 (en) * 1998-07-15 2000-01-27 Mandorlo Investment Gmbh Skin and tissue care and/or treatment agent
WO2000003689A3 (en) * 1998-07-15 2000-04-20 Mandorlo Investment Gmbh Skin and tissue care and/or treatment agent
US8759393B2 (en) 1998-11-19 2014-06-24 Biogen Idec International Gmbh Utilization of dialkylfumarates
US7915310B2 (en) * 1998-11-19 2011-03-29 Biogen Idec International Gmbh Utilization of dialkylfumarates
US8524773B2 (en) 1998-11-19 2013-09-03 Biogen Idec International Gmbh Utilization of dialkylfumarates
WO2003005979A3 (en) * 2001-07-07 2003-10-23 Beiersdorf Ag Cosmetic and dermatological preparations containing osmolytes for the treatment and active prevention of dry skin and of other negative alterations in the physiological homeostasis of healthy skin
WO2003005979A2 (en) * 2001-07-07 2003-01-23 Beiersdorf Ag Cosmetic and dermatological preparations containing osmolytes for the treatment and active prevention of dry skin and of other negative alterations in the physiological homeostasis of healthy skin
US8980832B2 (en) 2003-09-09 2015-03-17 Biogen Idec International Gmbh Use of fumaric acid derivatives for treating cardiac insufficiency, and asthma
US11052062B2 (en) 2004-10-08 2021-07-06 Biogen Swiss Manufacturing Gmbh Controlled release pharmaceutical compositions comprising a fumaric acid ester
US11229619B2 (en) 2004-10-08 2022-01-25 Biogen Swiss Manufacturing Gmbh Controlled release pharmaceutical compositions comprising a fumaric acid ester
US8399514B2 (en) 2007-02-08 2013-03-19 Biogen Idec Ma Inc. Treatment for multiple sclerosis
US8906420B2 (en) 2009-01-09 2014-12-09 Forward Pharma A/S Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix
US11173123B2 (en) 2009-01-09 2021-11-16 Biogen Swiss Manufacturing Gmbh Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix

Also Published As

Publication number Publication date
DE2840498C2 (en) 1980-04-10

Similar Documents

Publication Publication Date Title
DE3405581A1 (en) PHARMACEUTICAL COMPOSITION WITH METABOLIC AND ENERGY EFFECTIVENESS FOR USE IN HEART AND VESSEL THERAPY
DE2840498C2 (en) Pharmaceutical preparations for the treatment of psoriasis
DE3428406A1 (en) DENTAL CEMENT
DE2602030A1 (en) DIPHOSPHONOALCANCARBONIC ACIDS
EP0207193A2 (en) Synergetic combination of flupirtin and 4-acetamido-phenol
DE3543801C2 (en)
DE2703964A1 (en) Preparations contg. fumaric acid, glycine and opt. phosphate - for internal and external treatment of psoriasis
DE1667903C3 (en) Use of cysteine derivatives for the production of orally administrable agents for combating seborrhea
DE3809625C2 (en)
DE2221281C3 (en) Pharmaceutical preparations with anti-inflammatory and analgesic effects
DE3840744C2 (en) Activator for osteoblasts
DE3044753C2 (en)
DE2609147A1 (en) PROPIONIC ACID SALT BASED AMINO ACIDS
DE2635293A1 (en) SALT MIXTURE, IN PARTICULAR EASILY ASSIMILABLE MEDICINAL MIXTURE WITH INCREASED SOLUBILITY, CONTAINS CALCIUM SALTS AND / OR MAGNESIUM SALTS
DE2521905A1 (en) FUMARIC SALT OF 1-DIAETHYLAMINO-AETHYL-3-(P-METHOXYBENZYL)-1,2-DIHYDRO-QUINOXALIN-2-ONE, PROCESS FOR ITS PREPARATION AND PHARMACEUTICALS CONTAINING THIS COMPOUND
EP0098475A2 (en) Pharmaceutical composition, its manufacture and use
DE1941217C3 (en) Alpha square brackets on 2- (p-chlorophenoxy) -isobutyryril square brackets on-beta-nicotinoylglycol ester and process for its preparation
DE3528709A1 (en) ORAL CARE PRODUCTS
CH648208A5 (en) PHARMACEUTICAL AGENT FOR REDUCING ENDOGENIC OXALATE FORMATION.
DE2642714C2 (en) Aqueous carbohydrate solution for parenteral use
DE1936274C3 (en) Biguanide nicotinates, processes for their preparation and medicinal products containing them
DE2245826C3 (en) Salts of N-cyano-ethyl-N'-m-chlorophenyl-piperazine
EP0009657A1 (en) Diuretic compositions comprising 2,4-diamino-5-(4-amino-3,5-dimethoxybenzyl)-pyrimidine and a diuretic which causes excretion of potassium and their preparation
DE1418658A1 (en) Therapeutic preparations
DE3110190A1 (en) CEPHAPIRIN SALTS WITH AMINO ACIDS AND METHOD FOR THE PRODUCTION THEREOF

Legal Events

Date Code Title Description
8339 Ceased/non-payment of the annual fee